Next-generation protein therapeutics for autoimmune and hematologic diseases
Trubion focused on creating protein therapeutics for autoimmune and hematologic oncology diseases. The company's products were based on several novel technology platforms to enhance or extend antibody-based therapeutics. Trubion completed its IPO on NASDAQ in 2006 and was acquired by Emergent BioSolutions in 2010.